Rutul Shah Sells 15,342 Shares of Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. (NASDAQ:PGEN) COO Rutul Shah sold 15,342 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $7.50, for a total value of $115,065.00. Following the completion of the sale, the chief operating officer owned 468,865 shares in the company, valued at approximately $3,516,487.50. The trade was a 3.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Precigen Trading Up 1.9%

Shares of PGEN stock opened at $7.42 on Thursday. The company’s fifty day simple moving average is $5.96 and its two-hundred day simple moving average is $4.71. The stock has a market capitalization of $2.65 billion, a price-to-earnings ratio of -7.13 and a beta of 1.02. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 3.89. Precigen, Inc. has a 1 year low of $2.99 and a 1 year high of $7.72.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.06. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The firm had revenue of $54.98 million during the quarter, compared to the consensus estimate of $27.98 million. Precigen’s revenue was up 6322.7% on a year-over-year basis. As a group, analysts anticipate that Precigen, Inc. will post 0.25 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on PGEN shares. Zacks Research raised Precigen from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 5th. Wall Street Zen raised Precigen from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. Citigroup restated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Finally, HC Wainwright lifted their target price on Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.50.

More Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong PAPZIMEOS sales and profitability: Precigen reported that PAPZIMEOS generated $53.1 million in second-quarter net product revenue, more than double the prior quarter. The product’s performance helped the company achieve quarterly profitability and represents a significant commercial inflection point. Precigen second-quarter update
• Positive Sentiment: Pipeline progress supports the growth outlook: PRGN-2009 is advancing in HPV-driven cancers, and management highlighted broader potential for the AdenoVerse platform. The combination of growing product revenue and additional pipeline opportunities is strengthening the investment case. AdenoVerse platform and PRGN-2009 update
• Positive Sentiment: Favorable external sentiment: Zacks included PGEN among five biotech stocks worth considering, citing industry momentum, pipeline progress and the company’s portfolio. Recent coverage also notes a consensus “Moderate Buy” rating and a $14.50 price target, although analyst opinions remain mixed. Zacks biotech stock selection
• Positive Sentiment: Director buying: Director Nancy Agee purchased 3,411 shares at $7.23, increasing her ownership by 1.12%. The insider purchase may signal confidence in Precigen’s outlook.
• Neutral Sentiment: COO sales were administrative: COO Rutul Shah sold a combined 50,000 shares at approximately $7.50 under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. The transactions reduce his holdings but are less bearish than discretionary selling.
• Neutral Sentiment: Momentum and risk: PGEN reached a new one-year high, reinforcing bullish momentum, but elevated valuation expectations and the company’s historically negative net margin leave the stock sensitive to future sales and clinical updates. Precigen reaches a new one-year high

Hedge Funds Weigh In On Precigen

A number of institutional investors and hedge funds have recently made changes to their positions in PGEN. Xponance LLC grew its holdings in shares of Precigen by 21.3% during the fourth quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,496 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Precigen by 6.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 2,993 shares during the last quarter. Composition Wealth LLC boosted its position in shares of Precigen by 16.5% in the 4th quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 3,000 shares during the period. Intech Investment Management LLC boosted its position in shares of Precigen by 5.2% in the 4th quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock valued at $263,000 after purchasing an additional 3,137 shares during the period. Finally, Cetera Investment Advisers grew its stake in Precigen by 0.9% during the 1st quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company’s stock worth $1,449,000 after buying an additional 3,250 shares during the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.